Fulvestrant Impurities

Fulvestrant is used in postmenopausal women with hormone-related breast cancer that is advanced or has spread to other parts of the body.

per page
Impurity structure Parent Drug Name Name of Impurity Catalogue No. CAS No.
Carbamimidothioic Acid 9-Hydroxynonyl Ester Bromide Fulvestrant

Carbamimidothioic Acid 9-Hydroxynonyl Ester Bromide

VE006475 511545-93-0
Fulvestrant 1,2-bis(9-bromononyl)disulfane Fulvestrant

Fulvestrant 1,2-bis(9-bromononyl)disulfane

VE006480 N/A
Fulvestrant 4,4,5,5,5-Pentafluoropentanol Fulvestrant

Fulvestrant 4,4,5,5,5-Pentafluoropentanol

VE006476 148043-73-6
Fulvestrant 4,4,5,5,5-pentafluoropentyl methanesulfonate Fulvestrant

Fulvestrant 4,4,5,5,5-pentafluoropentyl methanesulfonate

VE006477 252947-01-6
Fulvestrant 9-[(4,4,5,5,5-Pentafluoropentyl)thio]nonanol Fulvestrant

Fulvestrant 9-[(4,4,5,5,5-Pentafluoropentyl)thio]nonanol

VE006478 511545-94-1
Fulvestrant 9-[[9-[(4,4,5,5,5-Pentafluoropentyl)sulfenyl]nonyl]sulfenyl]nonyl Bromide Fulvestrant

Fulvestrant 9-[[9-[(4,4,5,5,5-Pentafluoropentyl)sulfenyl]nonyl]sulfenyl]nonyl Bromide

VE006481 1391053-14-7
Fulvestrant CRS (Y0001399) Fulvestrant

Fulvestrant CRS (Y0001399)

PVE00260 129453-61-8
Fulvestrant EP Impurity A Fulvestrant

Fulvestrant EP Impurity A

VL234002 407577-53-1
Fulvestrant EP Impurity B Fulvestrant

Fulvestrant EP Impurity B

VL234004 98008-06-1
Fulvestrant EP Impurity C Fulvestrant

Fulvestrant EP Impurity C

VL234003 N/A
Fulvestrant EP Impurity D Fulvestrant

Fulvestrant EP Impurity D

VL234006 N/A
Fulvestrant EP Impurity E Fulvestrant

Fulvestrant EP Impurity E

VL234005 2170200-14-1
Fulvestrant EP Impurity F Fulvestrant

Fulvestrant EP Impurity F

VL234001 N/A
Fulvestrant for System Suitability CRS (Y0001413) Fulvestrant

Fulvestrant for System Suitability CRS (Y0001413)

PVE0077 129453-61-8
Fulvestrant Impurity 12 Fulvestrant

Fulvestrant Impurity 12

VE006804 2490287-82-4
Fulvestrant Impurity 13 Fulvestrant

Fulvestrant Impurity 13

VE006803 2490287-87-9
Fulvestrant-D3 Fulvestrant


DVE00862 N/A
(7alpha,17beta)-17-(Acetyloxy)-7-(9-bromononyl)estr-4-en-3-one Fulvestrant


VE008247 875573-63-0
17 Keto Fulvestrant Fulvestrant

17 Keto Fulvestrant

VL234007 403656-89-3
6-Dehydronandrolone Acetate Fulvestrant

6-Dehydronandrolone Acetate

VE008245 2590-41-2
7β-Acetyloxy-7α-[9-(dimethyl(tert-butylsilyloxy)nonyl]estr-4-en-3-one Fulvestrant


VE008246 875573-60-7

Fulvestrant Related Compound

Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy.


  • Farooq, Maheen, and Shivani P. Patel. “Fulvestrant.” Nih.gov, StatPearls Publishing, 25 July 2022, www.ncbi.nlm.nih.gov/books/NBK560854/
  • Fulvestrant Injection: MedlinePlus Drug Information.” Medlineplus.gov, 2019, medlineplus.gov/druginfo/meds/a607031.html.
  • Cleveland Clinic Cancer. “Faslodex – Drug Information – Chemocare.” Chemocare.com, 2023, chemocare.com/chemotherapy/drug-info/faslodex.aspx.


What is Fulvestrant?

Fulvestrant is used in the management and treatment of metastatic breast cancer. It is an estragon receptor degrader that is selective. This activity describes Fulvestrant’s indications, mechanism of action, and contraindications as a helpful medication in the treatment of advanced breast cancer.

Fulvestrant belong to which class ?

Fulvestrant belongs to a family of drugs known as oestrogen receptor antagonists. It works by preventing oestrogen from acting on cancer cells. Some breast cancers that require oestrogen to develop can be slowed or stopped by this.

What is the generic name of fluvestrant ?

Fulvestrant is available under the brand name Faslodex.